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ABSTRACT 34 
 35 
The development of a new tuberculosis vaccine is an urgent need due to the failure of the 36 
current vaccine, BCG, to protect against the respiratory form of the disease. MTBVAC is an 37 
attenuated Mycobacterium tuberculosis vaccine candidate genetically engineered to fulfil the 38 
Geneva consensus requirements to enter human clinical trials. We selected a M. 39 
tuberculosis clinical isolate to generate two independent deletions without antibiotic-40 
resistance markers in the genes phoP, coding for a transcription factor key for the regulation 41 
of M. tuberculosis virulence, and fadD26, essential for the synthesis of the complex lipids 42 
phthiocerol dimycocerosates (DIM), one of the major mycobacterial virulence factors. The 43 
resultant strain MTBVAC exhibits safety and biodistribution profiles similar to BCG and 44 
confers superior protection in preclinical studies. These features have enabled MTBVAC to 45 
be the first live attenuated M. tuberculosis vaccine to enter clinical evaluation.46 
 3 
 
1. Introduction 47 
 48 
The only vaccine against tuberculosis (TB) in use today, Bacille Calmette-Guerin (BCG), is a 49 
live attenuated strain of Mycobacterium bovis effective in reducing the rate of severe forms of 50 
TB (meningitis and miliary TB) in children, but is inconsistent in preventing spread of 51 
pulmonary TB, the most common form of the disease in adolescents and adults, which fuels 52 
the continuing epidemic [1, 2]. Developed a century ago by repeated subculture, the principal 53 
genetic basis for BCG attenuation is the loss of RD1 region, which encodes the machinery 54 
required to synthesize and export the major T-cell antigen/virulence factor ESAT-6/CFP-10 55 
[3, 4]. Subsequent worldwide distribution of BCG and repeated subculture in non-56 
standardized conditions has led to emergence of a number of daughter BCG sub-strains, 57 
which comprise natural mutants of well-recognized virulence factors, suggesting that some 58 
sub-strains may be more attenuated and otherwise less immunogenic than others [3, 5-7]. 59 
New vaccines able to prevent respiratory forms of TB will have a tremendous impact in 60 
preventing transmission and control of the disease [8-10]. 61 
 62 
We have previously described the construction of the SO2 strain by insertion of a kanamycin-63 
resistance cassette in the phoP gene of a M. tuberculosis clinical isolate [11]. PhoP is a key 64 
transcriptional regulator, which controls approximately 2% of M. tuberculosis coding capacity, 65 
including the synthesis of the immunomodulatory trehalose-derived lipids, diacyl- (DAT) and 66 
polyacyl-trehaloses (PAT), and the secretion of the virulence factor ESAT-6 [12-15]. Ten 67 
years of rigorous preclinical testing of SO2 as a vaccine candidate has provided robust data 68 
for its high degree of safety and improved immunogenicity and protective efficacy compared 69 
to BCG in relevant animal models of TB, from mice to non-human primates [16-19]. Despite 70 
the promising results, the establishment of the Geneva consensus for new live mycobacterial 71 
vaccines, demanding the presence of two stable independent mutations without antibiotic-72 
resistance markers for M. tuberculosis-based candidates, in addition to a safety and efficacy 73 
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profile at least comparable to BCG in the relevant animal models, rendered SO2 unsuitable 74 
for entry into clinical trials [20, 21]. 75 
 76 
Here we describe the construction and extensive preclinical characterization of MTBVAC, the 77 
first live-attenuated vaccine based on a M. tuberculosis human isolate that entered first-in-78 
human clinical evaluation in January 2013. This vaccine is based on the prototype SO2 and 79 
is genetically engineered to fulfil the Geneva consensus requirements for progressing new 80 
live mycobacterial vaccines into Phase 1 clinical trials, requiring two non-reverting unmarked 81 
independent mutations [20]. MTBVAC contains two stable deletions in the phoP and fadD26 82 
genes without antibiotic-resistance markers. FadD26 is essential for the synthesis of 83 
phthiocerol dimycocerosates (DIM), a family of surface lipids involved in M. tuberculosis 84 
virulence [22, 23]. MTBVAC is safe in all preclinical studies and confers superior protection in 85 
mice compared to the reference licensed strain BCG Danish 1331 used in the clinic.  86 
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2. Materials and Methods 87 
 88 
2.1. MTBVAC construction and culture conditions 89 
M. tuberculosis Mt103, the parental strain in this study, was isolated from an 90 
immunocompentent TB patient [24]. MTBVAC vaccine candidate was constructed following 91 
standard mycobacterial genetic-engineering protocols [25-27] (for a detailed description of 92 
the process see supplementary methods). 93 
Mycobacterial strains were grown at 37°C in Middlebrook 7H9 broth (Difco) supplemented 94 
with albumin, dextrose and catalase (ADC) (Difco) and 0.05% (v/v) Tween-80, or on solid 95 
Middlebrook 7H10 or 7H11 (Difco) supplemented with ADC (Difco). When required, 96 
kanamycin (20 g/ml) was added to the media. All chemicals were purchased from Sigma-97 
Aldrich except where indicated. 98 
 99 
2.2. Protein isolation and western-blot analysis 100 
Whole-cell proteins. Mycobacteria from early log-phase liquid cultures of Mt103 or MTBVAC 101 
were pelleted by centrifugation, washed and resuspended in phosphate-buffered saline 102 
(PBS) containing a cocktail of protease inhibitors. Cell suspensions were disrupted by 103 
sonication. 104 
Secreted proteins. M. tuberculosis strains were grown in 7H9 supplemented with dextrose (2 105 
g/l) and supernatants were separated by centrifugation. Secreted proteins were precipitated 106 
by incubation with 10% (v/v) trichloroacetic acid for 30 min on ice and then centrifuged at 4ºC 107 
for 30 min. Pelleted proteins were rinsed with cold acetone and resuspended in 150 mM Tris-108 
HCl pH=8. 109 
Western blot. Both protein preparations were sterilized using a 0.22-m low protein-binding 110 
filter (Pall) and quantified using the RC DC protein assay (BioRad). 5 g of protein were 111 
loaded per well and separated by SDS-PAGE. Immunodetection was carried out using 112 
primary monoclonal mouse antibodies anti-ESAT6 or anti-GroEL (Abcam), followed by 113 
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incubation with an anti-mouse secondary antibody and developed with a chemiluminiscent 114 
substrate (ImmobilonTM western, Millipore). 115 
 116 
2.3. Complex lipids extraction and thin-layer chromatography analysis 117 
Mt103 and MTBVAC strains were grown in 16 ml of liquid medium for 10 days (exponential 118 
phase). Radiolabelling of methyl-branched fatty acids was performed by incubating the 119 
cultures with 7 Ci of 14C-propionate (specific activity 55 mCi/mmol; MP Biomedicals) for 24h 120 
at 37°C with continuous agitation and mycobacterial lipids were then extracted as previously 121 
described [28]. Lipid profiles were analyzed by spotting equivalent amounts of crude extracts 122 
(resuspended in CHCl3) on silica gel G60 plates (Merck), which were then run in various 123 
solvent systems (CHCl3/CH3OH/H2O 60:16:2 (v/v) for DAT; CHCl3/CH3OH 99:1 (v/v) for PAT; 124 
and petroleum ether/diethyl ether 9:1 (v/v) for DIM). Radiolabeled lipids were visualized with 125 
a Typhoon PhosphorImager (Amersham Biosciences). 126 
 127 
2.4. Animal studies 128 
All the animals were kept under controlled conditions and observed for any sign of disease. 129 
Experimental work was conducted in agreement with European and national directives for 130 
protection of experimental animals and with approval from the competent local ethical 131 
committees. 132 
 133 
Mouse studies 134 
For immunogenicity studies, BALB/c mice (Charles River) were mock-treated or 135 
subcutaneously inoculated with 5x105 colony forming units (CFU) of reconstituted lyophilized 136 
MTBVAC, prototype SO2 or BCG Danish 1331. At 7, 28 and 60 days post-inoculation, 137 
splenocytes were collected from 4 animals per group and stimulated overnight with purified 138 
protein derivative (PPD) [16]. Intracellular staining of IFN was performed using BD 139 
Cytofix/Cytoperm Fixation/Permeabilization kit following manufacturer instructions.  140 
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For biodistribution studies, groups of male or female BALB/c mice (Charles River) received 141 
an intradermal injection of 5x105 CFU of reconstituted lyophilized MTBVAC or BCG Danish 142 
1331. At weeks 1, 2, 4, 8, 16 and 24 post-inoculation, 4 mice per group were randomly 143 
selected and sacrificed for enumeration of viable bacteria in inguinal and axillary lymph 144 
nodes, spleen, liver, lungs, kidneys, testis, ovaries and brain. Urine and stool samples were 145 
collected at each time point. Organs were homogenized and viable bacteria were counted by 146 
plating onto selective 7H11-ADC supplemented with antibiotics to avoid contamination. 147 
For protection studies, groups of 8 C57BL/6 mice (Janvier) were mock-treated or 148 
subcutaneously vaccinated with 5x105 CFU of reconstituted lyophilized MTBVAC or BCG 149 
Danish 1331. 8 weeks post-vaccination, mice were intranasally challenged with 100 CFU of 150 
virulent M. tuberculosis H37Rv. 4 weeks later, mice were humanely sacrificed and CFU 151 
quantified in lungs and spleen.  152 
For safety studies, groups of 12 CB-17/Icr Ico SCID mice (Charles River) received a single 153 
subcutaneous administration of 2.5x107 CFU (equivalent to 50 times the dose recommended 154 
for BCG in humans, 5x105) of vaccine strains MTBVAC, BCG Pasteur or BCG Danish 1331; 155 
a group was inoculated with 105 CFU of parental M. tuberculosis Mt103 as the virulence 156 
control. The endpoint of the experiment was defined as survival up to 13 weeks post-157 
inoculation and then animals were humanely euthanized and bacterial load in lungs and 158 
spleen was quantified. 159 
 160 
Guinea pig studies 161 
For protection studies, groups of 8 Dunkin-Hartley guinea pigs (Harlan) were mock-treated or 162 
subcutaneously vaccinated in the nape of the neck with 5x103, 5x104 and 5x105 CFU of 163 
reconstituted lyophilized MTBVAC, or 5x104 CFU of SO2 or BCG Danish 1331. 12 weeks 164 
post-vaccination, animals were subjected to an aerosol challenge of 10-50 CFU per lung of 165 
M. tuberculosis H37Rv (NCTC 7416) [29], using a Henderson apparatus [30]. Bacterial 166 
burden in lungs and spleen at 4 weeks post-challenge was quantified. The severity of the 167 
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microscopic lesions in lungs and spleen was also evaluated by a subjective histopathology 168 
scoring matrix [29].  169 
For shedding and excretion experiments, groups of 10 Dunkin-Hartley guinea pigs (5 males 170 
and 5 females) (Harlan), were intradermally vaccinated with 5x105 CFU of reconstituted 171 
lyophilized MTBVAC or BCG Danish 1331. Animals were observed over a period of 7 weeks 172 
post-vaccination during which samples (injection site swab, urine and stool) were collected at 173 
the selected time points and plated for the detection of possible vaccine shedding or 174 
excretion. Injection site swabs were collected at 0, 3, 7, 14, 21, 28, 35, 42 and 49 days post-175 
inoculation. In addition, swabs of the vaccine site were collected immediately on observation 176 
of a site „opening‟ event. Urine and stool samples were collected at 2, 7, 21 and 49 days 177 
post-inoculation. 178 
For safety studies, groups of 8 Dunkin-Hartley guinea pigs (Harlan) were subcutaneously 179 
vaccinated with 2.5x107 CFU (equivalent to 50 times the dose recommended for BCG in 180 
humans, 5x105) of reconstituted lyophilized MTBVAC or BCG Danish 1331. Animals were 181 
observed daily over a period of 42 days post-administration and body weights of all animals 182 
were recorded weekly. At the end of the experiment, animals were euthanized and examined 183 
for any signs of TB lesions in lungs, spleen, liver and lymph nodes. Any potential lesion was 184 
recovered and submitted for culture and/or fixed and submitted for histological assessment.  185 
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3. Results 186 
 187 
3.1. From SO2 to MTBVAC: generation of two unmarked deletions in phoP and fadD26 188 
genes to fulfil the Geneva consensus 189 
Considering that attenuation by two non-reverting independent mutations without antibiotic-190 
resistance markers is required to fulfil the Geneva consensus criteria, we sought to construct 191 
an SO2-based vaccine that accomplished these criteria for progressing this vaccine 192 
candidate into clinical evaluation [20]. We followed a stepwise approach to genetically 193 
engineer two stable deletions in phoP and fadD26 genes in the SO2 strain, with subsequent 194 
elimination of antibiotic-resistance markers, generating a novel vaccine candidate that was 195 
named MTBVAC (Fig. 1A). No significant differences in growth behaviour were observed 196 
between MTBVAC and SO2 in axenic culture (Fig. S3). 197 
To confirm the biochemical phenotype of MTBVAC, the lipid content of the cell wall envelope 198 
was analysed by thin-layer chromatography. This analysis confirmed that, due to fadD26 199 
deletion, the outermost layer of MTBVAC is devoid of DIM [22] (Fig. 1B), and that phoP 200 
inactivation renders MTBVAC unable to synthesize trehalose-derived lipids DAT and PAT 201 
[12] (Fig. 1C). In addition to these characteristic lipid deficiencies, the deletion of phoP in 202 
MTBVAC reduces the amount of intracellular ESAT-6 and prevents the secretion of this 203 
major virulence factor [14] (Fig. 1D).  204 
Once the in vitro phenotype provided by the phoP and fadD26 deletions was corroborated, 205 
MTBVAC was subjected to an extensive preclinical characterization to support its progress to 206 
clinical evaluation. 207 
 208 
3.2. MTBVAC has vaccine properties comparable to SO2 209 
To corroborate that the phenotypic equivalence of MTBVAC and SO2 translates to functional 210 
comparability, bridging studies for vaccine efficacy in guinea pigs and immunogenicity in 211 
mice were conducted. 212 
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First, mouse immunogenicity studies, using the clinical dose and route of administration, 213 
showed comparable results for MTBVAC and SO2 as measured by the percentage of splenic 214 
IFN-producing CD4+ cells, following stimulation with M. tuberculosis PPD, at different time 215 
points post-vaccination (Fig. S4).  216 
Second, in the guinea-pig short-term protection experiment, MTBVAC conferred statistically 217 
equivalent protection compared to SO2 both in lungs (Fig. 2A) and spleen (Fig. 2B). Similar 218 
protection was provided by all the tested doses of MTBVAC. A comparable protective 219 
efficacy was obtained with BCG (data not shown), as previously described for SO2 [16]. 220 
 221 
3.3. MTBVAC is as safe as the licensed vaccine BCG Danish 1331  222 
To support entry into clinical trials in Europe, a battery of preclinical studies of MTBVAC 223 
freeze-dried preparation, produced in compliance with Good Manufacturing Practices (GMP), 224 
was conducted in mice and guinea pigs, meeting Regulatory requirements in Spain (country 225 
of GMP manufacture) and in Switzerland (country of Phase 1 trial) in accordance with the 226 
European Pharmacopoeia monograph [31] and the WHO Recommendations to Assure the 227 
Quality, Safety and Efficacy of BCG freeze-dried vaccines for human use [32]. As BCG 228 
Danish 1331 is the only licensed TB vaccine in Europe, it was used as the reference 229 
comparator in the preclinical characterization of MTBVAC freeze-dried product. 230 
MTBVAC showed a comparable safety profile to BCG Danish 1331 in the survival 231 
experiment using immunocompromised SCID mice inoculated with 50 times the 232 
recommended human dose for BCG (Table 1). All the SCID mice inoculated with the vaccine 233 
strains survived to the end of the experiment. Equivalent bacterial loads both in lungs (Fig. 234 
3A) and spleen (Fig. 3B) were observed for MTBVAC and BCG Danish 1331. In contrast, 235 
mice in the Mt103 group died by week six post-inoculation and a significantly higher bacterial 236 
burden was observed. In the case of the guinea pig study, none of the animals inoculated 237 
with 50 times the BCG dose recommended for humans died or showed signs of TB in-life or 238 
at autopsy (table 1). 239 
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Vaccine biodistribution in mice was mainly in a localization restricted to lymphoid organs, 240 
especially lymph nodes where a peak of colonies was observed between two and four weeks 241 
post-vaccination, followed by progressive clearance thereafter (Fig. 4). In addition, MTBVAC 242 
and BCG Danish 1331 could not be detected in urine and stool (table 1). In guinea pigs, 243 
viable MTBVAC or BCG were uniquely found in the site of vaccination only immediately after 244 
administration. In the case of BCG, some “opening” events in the site of vaccination were 245 
observed (table 1).  246 
 247 
3.4. MTBVAC induces improved protection in mice 248 
Having established the comparable safety and biodistribution profile of MTBVAC and BCG 249 
Danish 1331 clinical lots, we conducted a preclinical protection experiment in mice to 250 
compare the efficacy of the two vaccines (table 1). Following a two-month vaccination by the 251 
clinical route and dose of administration, we compared the efficacy of MTBVAC and BCG 252 
Danish 1331 at one month post-challenge with virulent M. tuberculosis H37Rv (the reference 253 
laboratory strain) by the natural respiratory route of infection (Fig. 5). Even though both 254 
vaccines conferred significant protection compared to saline controls, a significantly higher 255 
reduction in bacterial burden was observed in MTBVAC group compared to BCG, both in 256 
lungs (Fig. 5A) and spleen (Fig 5B).  257 
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4. Discussion 258 
 259 
One of the main limitations presented with BCG is the large variability in protective efficacy 260 
afforded in clinic ranging from 0% to 80% [1, 2]. Thus, a better vaccine that can induce 261 
superior protection over BCG and which could last into adolescence and adulthood against 262 
pulmonary disease would have a tremendous impact on TB control programs [10]. MTBVAC 263 
is the first M. tuberculosis-based vaccine candidate to fulfil the Geneva consensus 264 
requirements for progressing new live tuberculosis vaccines to clinical trials [20]. Two 265 
unmarked deletions have been engineered in the genes phoP and fadD26 to render the final 266 
vaccine construct phenotypically comparable to the vaccine prototype SO2 (Fig. 1). 267 
 268 
MTBVAC is a derivative of a clinical isolate of M. tuberculosis, a classical approach to human 269 
vaccinology. Most of the whole cell live vaccines used in human immunization schedules, 270 
except for small pox, TB and rotavirus infections, are based on the attenuated pathogen from 271 
human origin [33]. MTBVAC is a derivative of a clinical isolate of M. tuberculosis, a classical 272 
approach to human vaccinology. The scientific rationale behind an M. tuberculosis-based 273 
vaccine that could replace BCG is that the latter is derived from the bovine pathogen M. 274 
bovis, an animal adapted close relative of M. tuberculosis which lost a series of genes in its 275 
genome in the process of its co-evolution with the immune system of its natural host. In 276 
addition, when compared to M. tuberculosis clinical isolates, more than one hundred genes 277 
are absent in BCG genome [3, 34]. These M. tuberculosis-restricted genes must be 278 
important in the successful interaction with the human immune system. Therefore, a vaccine 279 
based on a human pathogen should be more effective at inducing more specific protective 280 
immunity against TB in the clinic. To demonstrate this rationale it is imperative to go to 281 
human efficacy trials, provided that the current animal models for TB are exhausted. 282 
Remarkably, all the current TB vaccine strategies under clinical evaluation are based on 283 
BCG [35, 36]. Consequently, the use of a vaccine based on the human pathogen as 284 
MTBVAC is a novel strategy. 285 
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 286 
Results obtained in immunogenicity (Fig. S4) and protective efficacy (Fig. 2) bridging 287 
experiments provide evidence that MTBVAC is functionally comparable to its prototype SO2 288 
and, therefore, data generated in preclinical studies with SO2 were accepted by the Swiss 289 
Regulatory Authorities as valid to support MTBVAC Phase 1 clinical evaluation. SO2 proved 290 
to be safe in guinea pigs and was more attenuated than BCG Pasteur in severe combined 291 
immunodeficiency (SCID) mice [16, 18]. In addition, SO2 conferred better protection than 292 
BCG Danish 1331 in a high-dose challenge long-term protection model in guinea pigs [16, 293 
29]. SO2 also showed improved reduction of lung bacillary burden in rhesus macaques when 294 
compared to BCG [19]. Finally, immunogenicity data in mice showed that SO2 was able to 295 
induce a higher differentiation of antigen-specific CD4+ T cells into central memory T cells, 296 
which correlated with longer protective efficacy in this model [37]. This latter result is 297 
especially important because some authors hypothesize that this inconsistent efficacy 298 
conferred by BCG may concern insufficient induction of long-lived memory T-cell responses 299 
[38]. 300 
 301 
 302 
5. Conclusions 303 
 304 
Data shown provide evidence that MTBVAC is functionally and phenotypically comparable to 305 
its prototype SO2. The results of these studies fulfil the first and second Geneva consensus 306 
safety requirements for entry into clinical trials of live attenuated M. tuberculosis vaccines 307 
[20, 21]. The absence of front-line lipids, lack of ESAT-6 secretion and down-expression of 308 
the PhoP regulon, essential for virulence and pathogenesis of M. tuberculosis, may explain 309 
the satisfactory safety profile of MTBVAC. 310 
 311 
Altogether, the improved protection levels against TB disease achieved by prototype SO2 312 
and MTBVAC in mice, guinea pigs and non-human primates and the rigorous preclinical 313 
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safety and biodistribution data presented in this work have satisfied the Regulatory 314 
Authorities and enabled MTBVAC to be the first M. tuberculosis vaccine candidate to enter 315 
human clinical evaluation, positioning MTBVAC as a reliable vaccine for human use with 316 
potential to replace BCG. 317 
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Figure legends 440 
 441 
Figure 1. From SO2 to MTBVAC: step-by-step construction (A) and biochemical 442 
characterization of MTBVAC (B-D). (A) Deletions in fadD26 and phoP genes were 443 
genetically engineered in SO2 strain. The final strain MTBVAC is a DIM-deficient phoP 444 
mutant which provides better assurance of genetic stability and has no antibiotic-resistance 445 
markers, fulfilling the Geneva consensus requirements. phoP and fadD26 genes are 446 
represented as grey arrows, white rectangles illustrate antibiotic-resistance markers and 447 
black arrow-heads depicts res sites. Vertical discontinuous lines indicate the position of 448 
restriction sites used for strain construction and horizontal discontinuous lines depict DNA 449 
regions that are not to scale. (B-C) Thin-layer chromatography analysis showing that 450 
MTBVAC is devoid of cell-wall lipids DIM (B) and DAT/PAT (C), as direct consequence of 451 
fadD26 and phoP deletions, respectively. Compounds of interest are indicated by arrow-452 
heads. (D) The absence of ESAT-6 secretion, characteristic of M. tuberculosis phoP 453 
mutants, was tested by Western blot. 454 
 455 
Figure 2. Bridging efficacy studies of MTBVAC and SO2 in Guinea Pigs.  Guinea pigs 456 
received a subcutaneous administration of the indicated doses of MTBVAC (white, grey and 457 
black diamonds) or SO2 (black circles), or not vaccinated (white squares), followed by an 458 
aerosol challenge with virulent H37Rv. At 4 weeks post-challenge, bacterial burden was 459 
assessed in lungs (A) and spleen (B). Comparable CFU reduction was observed with SO2 460 
and the three tested doses of MTBVAC. Data are expressed as Mean ± SEM and compared 461 
by non-parametric Mann-Whitney test. ***, P < 0.001. 462 
 463 
Figure 3. MTBVAC safety in SCID mice. SCID mice received a single subcutaneous 464 
administration of MTBVAC (black), BCG Danish 1331 (dark grey) or BCG Pasteur (light grey) 465 
equivalent to 50 times the dose recommended for BCG in humans. A group inoculated with 466 
one single dose of virulent Mt103 was used as control (white). CFU in lungs (A) and spleen 467 
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(B) were determined at the endpoint of the experiment (13 weeks), except for Mt103-infected 468 
animals which died by week 6. All the animals inoculated with the vaccine strains survived 469 
until the end of the experiment and presented comparable bacterial burden. Data are 470 
expressed as Mean ± SEM and compared using unpaired Student‟s t test. ***, P < 0.001.  471 
 472 
Figure 4. MTBVAC biodistribution profile. BALB/c mice were intradermally inoculated with 473 
MTBVAC (black diamonds) or BCG Danish 1331 (white circles) and bacterial load in lymph 474 
nodes was determined. A similar clearance profile was obtained for both strains. Data are 475 
expressed as Mean ± SEM and compared using unpaired Student‟s t test. *, P < 0.05; **, P < 476 
0.01. 477 
 478 
Figure 5. Protective efficacy of MTBVAC in mice. C57BL/6 mice received a subcutaneous 479 
administration of MTBVAC (black diamonds) or BCG Danish 1331 (white circles), or were not 480 
vaccinated (white squares), followed by an intranasal challenge with virulent H37Rv. At 4 481 
weeks post-challenge, bacterial burden was assessed in lungs (A) and spleen (B). 482 
Significant CFU reduction was observed in MTBVAC vaccinated animals compared to BCG. 483 
Data are expressed as Mean ± SEM and compared using unpaired Student‟s t test. *, P < 484 
0.05; **, P < 0.01; ***, P < 0.001. 485 
 486 
Supplementary figure 1. Verification of fadD26 deletion and subsequent elimination of 487 
the antibiotic-resistance marker. (A, C) Schematic representation of fadD26 genomic 488 
region in Mt103 (A, C), SO2fadD26::hyg (A) and SO2fadD26 (C). Location of specific 489 
primers is represented above by arrow-heads and approximated expected sizes for the PCR 490 
products are indicated below. (B, D) PCR analysis of the strains using the primer 491 
combinations indicated in left panels (A, C). 492 
 493 
Supplementary figure 2. Verification of phoP deletion and subsequent elimination of 494 
the antibiotic-resistance marker. (A, C) Schematic representation of phoP genomic region 495 
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in Mt103 (A, C), SO2fadD26phoP::hyg (A) and MTBVAC (C). Location of specific primers 496 
is represented above by arrow-heads and approximated expected sizes for the PCR 497 
products are indicated below. (B, D) PCR analysis of the strains using the primer 498 
combinations indicated in left panels (A, C). 499 
 500 
Supplementary figure 3. In vitro growth characterization of MTBVAC. (A) Growth 501 
kinetics of Mt103 (squares), SO2 (circles) and MTBVAC (diamonds) was studied in 7H9 502 
liquid medium by measuring the optical density at 600 nm (OD600nm) (filled symbols) and CFU 503 
counts (open symbols). (B) Colony morphology of the strains on solid 7H10 medium. No 504 
major differences in the growth rate of the three strains were observed in liquid broth, while 505 
colonies were smaller for both vaccine candidates on solid medium. 506 
 507 
Supplementary figure 4. Bridging immunogenicity study of MTBVAC and SO2. BALB/c 508 
mice were inoculated with MTBVAC (black), SO2 (dark grey) or BCG Danish 1331 (light 509 
grey), or not vaccinated (white), and immunogenicity was measured as the percentage of 510 
IFN+ CD4+ splenocytes. MTBVAC and SO2 induce equivalent T-cell responses at all the 511 
studied post-inoculation time-points. Data are expressed as Mean ± SEM.  512 
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Supplementary methods 513 
 514 
1. Construction of plasmids  515 
E. coli strains, used for cloning processes, were grown at 37°C in LB broth or agar plates. 516 
Media were supplemented with ampicillin (100 g/ml), gentamicin (Gm) (15 g/ml), 517 
kanamycin (Km) (20 g/ml) or hygromycin (Hyg) (50 g/ml), when necessary. The same 518 
strategy was used for the construction of the plasmids for fadD26 (pAZ5) and phoP (pAZ18) 519 
inactivation (table S1). DNA fragments containing the fadD26 or phoP genes were amplified 520 
from M. tuberculosis H37Rv genomic DNA using primers fadD26F and fadD26R or phoPF 521 
and phoPR [12] (table S1), respectively, and cloned in pGEM-T Easy (Promega). An EcoRV-522 
BamHI fragment from pWM27 [25], containing a res-hyg-res cassette, was inserted 523 
between either BamHI and EcoRV sites in fadD26 (1,511-bp deletion) or EcoRV and BclI in 524 
phoP (94-bp deletion). The fragments containing the deleted fadD26 or phoP genes, and 525 
their flanking regions, were then released by digestion with XhoI and subsequently inserted 526 
in pJQ200-xylE [26] (table S1), a mycobacterial suicide plasmid containing the counter-527 
selectable marker sacB and the reporter gene xylE. 528 
A resolvase expression plasmid carrying a Km-resistance cassette, pAZ20 (table S1), was 529 
constructed by inserting the BsaBI-SphI fragment from plasmid pPR23 [27] containing the 530 
sacB gene and a Gm-resistance cassette, between SphI and SfoI sites in pCG124 [25]. 531 
 532 
2 Construction of MTBVAC vaccine candidate 533 
Except where indicated, mycobacterial strains were grown at 37°C in Middlebrook 7H9 broth 534 
(Difco) supplemented with ADC (Difco) and 0.05% Tween-80, or on solid Middlebrook 7H10 535 
(Difco) supplemented with OADC (ADC plus oleic acid) (Difco). When required, Km, Hyg (20 536 
g/ml), Gm (10 g/ml) or 2% (w/v) sucrose (Suc) were added to the media. 537 
SO2 strain was electrotransformed with pAZ5 (table S1) and allelic exchange events were 538 
selected in two steps. Transformants were selected on Hyg-containing plates and single 539 
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colonies were assayed for Suc sensitivity. In the second step, two HygR SucS colonies were 540 
propagated in liquid medium to allow a second recombination event to occur, and serial 541 
dilutions were plated on Suc-containing plates to select bacteria that had lost the sacB gene. 542 
To discard false-positives due to mutations in sacB gene, a XylE activity assay (by spreading 543 
a catechol solution) was performed. HygR SucR clones were tested by PCR using various 544 
combinations of primers located either in the fadD26 deleted region (fadD26I1, fadD26I2; 545 
table 1) or hybridizing in the res site (res1, res2; table S1) [25] and outside the fadD26-546 
flanking regions cloned in pAZ5 (fadD26up, fadD26down; table S1 & Fig. S1A). One clone 547 
giving the pattern corresponding to allelic exchange was retained to continue the 548 
construction and named SO2fadD26::hyg (Fig 1A & Fig. S1B). Then, to eliminate the Hyg-549 
resistance marker, pWM19 [25] (table S1) was introduced in SO2fadD26::hyg strain and 550 
transformants were selected at 30°C on Gm-containing plates. Two transformants were 551 
grown until saturation in liquid broth at 30°C to allow resolvase expression, and serial 552 
dilutions were plated on Suc-supplemented plates and incubated at 39°C forcing loss of 553 
pWM19. Several clones were tested for Hyg and Gm sensitivity and by PCR using primers 554 
fadD26F and fadD26R (table S1 & Fig S1C). Sequencing of the PCR product obtained from 555 
the selected clone SO2fadD26 confirmed the presence of one copy of res site as “scar” of 556 
the resolution process (Fig 1A & Fig. S1D). 557 
Next step was the replacement of the Km-resistance cassette inserted in phoP gene in SO2 558 
strain by a deletion containing a res-flanked cassette. SO2fadD26 was electrotransformed 559 
with pAZ18 (table S1) and allelic exchange events were selected as described above to 560 
obtain the strain SO2fadD26phoP::hyg (Fig. 1A) and PCR analysis was performed using 561 
various combinations of specific primers (res1, res2, phoPF, phoPR; table S1 & Fig S2A-B) 562 
to confirm homologous recombination. Finally, plasmid pAZ20 (table S1) was introduced in 563 
SO2fadD26phoP::hyg to generate the phoP unmarked mutant. Transformants were 564 
selected on Km-containing plates, grown until saturation in liquid medium and plated on Suc-565 
supplemented plates. Clones obtained were tested by PCR using primers phoRF and phoPR 566 
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(table S1 & Fig. S2C) and one clone giving the appropriate PCR product was selected and 567 
named MTBVAC (Fig. 1A & Fig. S2D).  568 
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Table 1. Summary of the preclinical studies conducted with final MTBVAC product to 569 
support entry into clinical trials 570 
 571 
Study Description 
Animal 
species 
Duration 
(weeks) 
Laboratory Results 
Safety 50 
human doses 
Survival; CFU in 
lungs and spleen 
SCID mice 13 
Germans 
Trias I Pujol 
Survival & CFU 
recovered 
equivalent to BCG 
Survival; 
histopathology 
Guinea pigs 6 Biofabri 
Survival & 
absence of TB 
lesions 
Biodistribution,  
Excretion & 
Shedding 
CFU in lungs, 
liver, kidneys, 
spleen, local 
lymph nodes, 
brain and gonads   
BALB/c 
mice 
22-24 
University 
of Zaragoza 
Biodistribution 
equivalent to BCG 
Excretion in urine 
and stool 
Absence of 
excretion 
Excretion in urine 
and stool & 
Shedding at 
vaccination site 
Guinea pigs 7 PHE 
Absence of 
excretion 
Protection 
CFU in lungs and 
spleen 
C57BL/6 
mice 
4 post-
vaccination 
University 
of Zaragoza 
Protection 
superior to BCG 
572 
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Table S1. Bacterial strains, plasmids and primers used in this study 573 
Mycobacterial 
strains 
Description Reference 
Mt103 Parental M. tuberculosis clinical isolate [24] 
SO2 phoP insertion mutant in Mt103 (KmR) [11] 
MTBVAC 
Double unmarked phoP and fadD26 deletion mutant 
in Mt103 (constructed from SO2) 
This work 
BCG Pasteur Laboratory reference BCG strain 
Our laboratory 
collection 
BCG Danish 
1331 
Only licensed BCG vaccine in Europe 
Our laboratory 
collection 
Plasmids Description Reference 
pJQ200-xylE 
Mycobacterial suicide plasmid carrying the 
counterselectable marker sacB and the reporter 
gene xylE (gmR) 
[26] 
pWM27 
Plasmid harboring the res-hygR-res cassette 
(hygR) 
[25] 
pAZ5 
pJQ200-xylE derivative containing a deleted copy of 
M. tuberculosis fadD26 gene (hygR, gmR) 
This work 
pAZ18 
pJQ200-xylE derivative containing a deleted copy of 
M. tuberculosis phoP gene (hygR, gmR) 
This work 
pWM19 
Mycobacterial thermo-sensitive plasmid for 
resolvase  expression, harboring the 
counterselectable marker sacB (hygR, gmR) 
[25] 
pCG124 
Mycobacterial plasmid for resolvase  expression 
(kmR) 
[25] 
pPR23 
Mycobacterial thermo-sensitive plasmid carrying the 
counterselectable marker sacB (hygR, gmR) 
[27] 
pAZ20 
Mycobacterial plasmid for resolvase  expression, 
harboring the counter selectable marker sacB (kmR, 
gmR) 
This work 
Primers Nucleotide sequence Reference 
fadD26F 5‟-CTCGAGTTCTCTATCCGTGTATTC-3‟ This work 
fadD26R 5‟-CTCGAGGTTGGTCTTGACAG-3‟ This work 
phoPF 5‟-AATCTAGATCAAGCATCAGCCGAGGTAC-3‟ [12] 
phoPR 5‟-AATCTAGAGATCACCCGAACGTAGAACC-3‟ [12] 
fadD26I1 5‟-CACGAATGTCATTGCCAATG-3‟ This work 
fadD26I2 5‟-GCTTGAGCATGACCTCTTCG-3‟ This work 
fadD26up 5‟-CAACGCAAGACGACATGG-3‟ This work 
fadD26down 5‟-GCACCGTCTTGATGAAGC-3‟ This work 
res1 5‟-CTAGAGCAACCGTCCGAAATATTATAA-3‟ [25] 
res2 5‟-GATCTCATAAAAATGTATCCTAAATCAAATATC-3‟ [25] 
phoRF 5‟- AATCTAGAGGGCAAGGGCAACAAGGAAC-3‟ This work 
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